Please use this identifier to cite or link to this item: https://repositorio.usj.es/handle/123456789/917

Full metadata record
DC FieldValueLanguage
dc.contributor.authorSerrano Barcos, Laura-
dc.contributor.authorAlgarate Cajo, Sonia-
dc.contributor.authorHerrero Cortina, Beatriz-
dc.contributor.authorBueno, Jessica-
dc.contributor.authorGonzalez-Barriga, Maria T.-
dc.contributor.authorDucons, Maria-
dc.contributor.authorMontero-Marco, Jesica-
dc.contributor.authorAcha, Beatriz-
dc.contributor.authorBlanco Taboada, Ana Laura-
dc.contributor.authorSanz-Burillo, Pilar-
dc.contributor.authorYuste, Cristina-
dc.contributor.authorBenito, Rafael-
dc.date.accessioned2023-05-29T15:09:46Z-
dc.date.available2023-05-29T15:09:46Z-
dc.date.issued2022-09-
dc.identifier.citationLaura Serrano and others, Assessment of humoral immune response to two mRNA SARS‐CoV‐2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection, Journal of Applied Microbiology, Volume 133, Issue 3, 1 September 2022, Pages 1969–1974, https://doi.org/10.1111/jam.15699en_US
dc.identifier.issn1365-2672en_US
dc.identifier.urihttps://repositorio.usj.es/handle/123456789/917-
dc.description.abstractAims: Presence of anti-S1region of SARS-CoV-2 spike protein was analysed, at two and eight months, in 477 immunocompetent healthcare workers in Zaragoza, Spain, vaccinated with mRNA-1273 (Moderna) or BNT162b2 (Pfizer). Methods and results: Antibody analysis was performed with Alinity i System (Abbott). At 2 months, 100% of vaccinated had anti-S1 IgG (mean = 13,285 AU ml−1). This value was significantly higher with Moderna (18,192 AU ml−1) than with Pfizer (10,441 AU ml−1). The mean value of anti-S1 IgG after vaccination was significantly higher in patients with than without previous infection (18,539 vs. 7919 AU ml−1); in both groups was significantly higher with Moderna than with Pfizer (21,881 vs. 15,733 AU ml−1 and 11,949 vs. 6387 AU ml−1), respectively. At 8 months, 100% of patients were IgG positive, with higher levels with Moderna than with Pfizer. Nevertheless, in ensemble of cases, a mean decrease of antibody levels of 11,025 AU ml−1 was observed. Conclusion: At 2 and 8 months after vaccination, IgG response persists with both vaccines but with important decrease which suggests the need for revaccination. Significance and impact of study: The study contributes to know the immune status after vaccination with two of more used anti-SARS-CoV-2 vaccines. This knowledge is important for establishing the best vaccination strategyen_US
dc.format.extent6 p.en_US
dc.format.mimetypeapplication/pdfen_US
dc.language.isoengen_US
dc.publisherWILEYen_US
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAnti-S IgG SARS-CoV- 2en_US
dc.subjectHealthcare workersen_US
dc.subjectImmune responseen_US
dc.subjectModernaen_US
dc.subjectmRNA SARS-CoV- 2 vaccinesen_US
dc.subjectPfizeren_US
dc.subjectPost-vaccinationen_US
dc.subjectRIPOVACen_US
dc.titleAssessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infectionen_US
dc.typejournal articlees_ES
dc.identifier.doihttps://doi.org/10.1111/jam.15699en_US
dc.rights.accessRightsopen accesses_ES
Appears in Collections:Artículos de revistas



This item is licensed under a Creative Commons License Creative Commons